Palmitoylethanolamide is a fat-based compound the body makes itself, also sold as a supplement, valued for calming overactive immune cells and quieting pain. Its strongest support is easing several kinds of long-standing pain, with benefit building over the first two months of daily use. Side effects are uncommon and mild; benefits for aging remain promising but unproven. (Full Review)

Protocol

Dose

600–1,200 mg/day

Micronized or ultramicronized PEA

Schedule

1,200 mg loading

1–2 months, then 600 mg daily maintenance

Administration

Split, with food

Often 600 mg twice daily, taken with a meal

Time to effect

First relief

1–2 weeks

Initial pain reduction may appear

Full effect

4–8 weeks

Pain relief builds substantially

Neuropathy

1–3 months

Gradual, most evident with micronized forms

Benefits

High: Chronic pain reduction

Medium: Reduced inflammation and neuroinflammation; diabetic and other peripheral neuropathy relief

Low: Improved sleep quality; cognitive and brain-aging support

Speculative: Exercise recovery and muscle adaptation; immune and respiratory resilience

Contraindications

Pregnancy

Breastfeeding

Known allergy to product excipients or source material

Key Interactions

Analgesics or anti-inflammatory medications

OTC NSAIDs (ibuprofen, naproxen) and acetaminophen

Anti-inflammatory/neuro-supportive supplements (luteolin, polydatin, alpha-lipoic acid, omega-3)

Curcumin, CBD

Risk & Side Effects

Medium: Mild gastrointestinal effects

Low: Theoretical allergy or sensitivity to source material; unknowns from limited long-term and special-population data

Speculative: Reduced efficacy from sub-optimal products

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation that PEA aims to lower
Pain score (0–10)	≥ 2-point or ≥ 30% drop	Primary measure of whether PEA is working
HbA1c	< 5.4%	Glycemic control if using PEA for diabetic neuropathy
Fasting glucose	70–85 mg/dL	Context for neuropathy and metabolic health

Cadence: Reassess symptoms at 4 and 8 weeks, then every 3–6 months

Qualitative Assessment

Sleep quality: easier falling asleep and feeling rested
Energy levels: reduced pain-related fatigue, greater daytime energy
Cognitive clarity: subjective "brain fog" or focus changes
Functional capacity: daily activities or exercise with less pain

Palmitoylethanolamide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment